Stenquist B, Wennberg A M, Gisslén H, Larkö O
Dept of Dermatology, Sahlgren's Hospital, Gothenburg, Sweden.
J Am Acad Dermatol. 1992 Jul;27(1):65-9. doi: 10.1016/0190-9622(92)70158-c.
Intralesional interferon has shown activity in the treatment of noduloulcerative and superficial basal cell carcinomas (BCC).
Our purpose was to study the efficacy of intralesional interferon in the treatment of aggressive BCCs.
Fifteen patients with histologically proven primary morpheaform or recurrent BCCs were referred for Mohs surgery. They received nine intralesional injections of 1.5 million IU of interferon alfa-2b three times a week for 3 weeks (total dose 13.5 million IU). All tumors were located on the face and measured 7 to 25 mm in diameter.
In four patients (27%) no residual tumor was found at surgery. In five (33%) tumor size was reduced by 75%. The remaining six patients (40%) showed no response to intralesional interferon.
At the dosage used, interferon was able to cure only a minority of aggressive BCCs.
病灶内注射干扰素已显示出对结节溃疡性和浅表性基底细胞癌（BCC）的治疗活性。
我们的目的是研究病灶内注射干扰素治疗侵袭性基底细胞癌的疗效。
15例经组织学证实为原发性硬斑病样或复发性基底细胞癌的患者被转诊接受莫氏手术。他们每周接受3次病灶内注射150万国际单位的α-2b干扰素，共9次，持续3周（总剂量1350万国际单位）。所有肿瘤均位于面部，直径为7至25毫米。
4例患者（27%）在手术时未发现残留肿瘤。5例（33%）肿瘤大小缩小了75%。其余6例患者（40%）对病灶内注射干扰素无反应。
在所使用的剂量下，干扰素仅能治愈少数侵袭性基底细胞癌。
